一位中國著名重癥監(jiān)護醫(yī)生表示,高血壓患者死于新冠肺炎的風險更高。自一月中旬以來,這位醫(yī)生一直在治療重癥患者。
雖然到目前為止還沒有任何研究報告解釋相關(guān)原因,但在最早發(fā)現(xiàn)病毒的武漢,醫(yī)生們發(fā)現(xiàn)患有基礎(chǔ)病的病毒感染者更有可能發(fā)展成重癥和死亡。
武漢一月份的170例死亡病例是新型冠狀病毒導(dǎo)致的首批死亡病例,這其中接近一半患有高血壓。
北京協(xié)和醫(yī)院重癥監(jiān)護室主任杜斌在武漢接受了彭博社的電話采訪。他表示:“這是非常高的比例?!眱蓚€月前,杜斌與許多頂級醫(yī)生一起馳援受災(zāi)的武漢市,幫助當?shù)蒯t(yī)院救治病人。
杜斌是中國最受尊敬的重癥監(jiān)護專家之一。他表示:“根據(jù)其他醫(yī)生的講述和我所看到的數(shù)據(jù),在所有基礎(chǔ)病中,高血壓是一個關(guān)鍵的危險因素。雖然目前還沒有發(fā)表相關(guān)研究報告,但我們認為高血壓可能是導(dǎo)致患者病情惡化和出現(xiàn)預(yù)后不良的重要因素?!?/p>
疫情在歐洲和美國的快速蔓延,使意大利等許多國家陷入危機。醫(yī)生正在努力應(yīng)對這種具有高傳染性的病原體。據(jù)世界衛(wèi)生組織,截至3月13日,在短短三個月內(nèi),全球已經(jīng)有超過13萬人感染了新型冠狀病毒,近5000人死亡。
面對這場全球蔓延的疫情,了解這種疾病的病程,識別面臨風險最高的人群,對于優(yōu)化治療方案至關(guān)重要。
我們可能需要研究中國龐大的患者群體才能找到答案。目前中國有15,000多名患者仍在住院治療,但新感染病例已經(jīng)大幅減少。有6%的患者病情惡化,并且惡化速度非??臁?/p>
杜斌說:“我們會密切關(guān)注老年人和高血壓患者。他們是我們工作的重點?!?/p>
除了高血壓以外,杜斌對新冠肺炎的治療還提出了以下觀點:
大膽使用呼吸機
杜斌說,當患者出現(xiàn)呼吸困難時,醫(yī)生應(yīng)該毫不猶豫地采取進一步措施,因為患者可能很快就出現(xiàn)器官衰竭。這意味著當微創(chuàng)輔助呼吸措施無法提高血氧飽和度時,醫(yī)生應(yīng)該積極干預(yù),采用有創(chuàng)通氣措施,在患者咽喉部位插管或者切開咽喉形成氣道。
他表示,需要有創(chuàng)機械通氣的患者接近一半最終死亡,但大多數(shù)康復(fù)患者都是很早就接受了有創(chuàng)通氣。
他說:“患者需要盡早使用有創(chuàng)通氣,沒有必要拖到太晚?!?/p>
專攻通氣和氧氣治療的呼吸科醫(yī)生,對于治療Covid-19重癥患者變得越來越重要,因為他們掌握更多相關(guān)知識,可以根據(jù)患者的情況調(diào)整呼吸機。
沒有“靈丹妙藥”
人們對開發(fā)治療這種病毒的藥物期望越來越高。正在測試治療方法的制藥公司獲得了投資者青睞,市值增加了數(shù)十億美元。但杜斌認為,僅靠藥物救不了患者,尤其是重癥患者。
他說,17年前的非典疫情導(dǎo)致近8000人感染。那次疫情的經(jīng)驗證明,多數(shù)患者沒有特定的抗病毒藥物就能治愈。他補充說,大量使用抗生素并沒有阻止細菌感染導(dǎo)致的死亡。
“當出現(xiàn)病毒感染的時候,我們都希望有一種藥物能殺死病毒,改變臨床結(jié)果。但實際上并沒有靈丹妙藥?!?/p>
相反,他認為,重癥監(jiān)護病房里專科醫(yī)生和護士團結(jié)合作,對于維持患者的生命更加重要。他說:“在重癥監(jiān)護病房里,醫(yī)生的工作應(yīng)該像管弦樂隊的指揮一樣,提供維持生命的治療,同時考慮不同專家的意見。”
再次感染的威脅
有報道稱,康復(fù)出院的患者再次檢測呈陽性甚至死亡,這引發(fā)了人們對于這種病毒可能以某種形式重新出現(xiàn)的擔憂。
但杜斌表示,患者在出院后幾天內(nèi)再次感染,“在理論上”沒有任何意義,因為患者血液中與病毒抗爭產(chǎn)生的抗體雖然不會一直存在,但也不會這么快消失。
他說:“對于復(fù)陽的患者,我們需要關(guān)注的是他們的陰性檢測結(jié)果的真實性?!崩纾鶕?jù)病毒所在的位置,對從同一位患者不同部位提取的樣本,可以進行不同的檢測。
他認為,不同廠家生產(chǎn)的檢測試劑盒也可能不一致,這也會影響檢測結(jié)果。(財富中文網(wǎng))
譯者:Biz
一位中國著名重癥監(jiān)護醫(yī)生表示,高血壓患者死于新冠肺炎的風險更高。自一月中旬以來,這位醫(yī)生一直在治療重癥患者。
雖然到目前為止還沒有任何研究報告解釋相關(guān)原因,但在最早發(fā)現(xiàn)病毒的武漢,醫(yī)生們發(fā)現(xiàn)患有基礎(chǔ)病的病毒感染者更有可能發(fā)展成重癥和死亡。
武漢一月份的170例死亡病例是新型冠狀病毒導(dǎo)致的首批死亡病例,這其中接近一半患有高血壓。
北京協(xié)和醫(yī)院重癥監(jiān)護室主任杜斌在武漢接受了彭博社的電話采訪。他表示:“這是非常高的比例?!眱蓚€月前,杜斌與許多頂級醫(yī)生一起馳援受災(zāi)的武漢市,幫助當?shù)蒯t(yī)院救治病人。
杜斌是中國最受尊敬的重癥監(jiān)護專家之一。他表示:“根據(jù)其他醫(yī)生的講述和我所看到的數(shù)據(jù),在所有基礎(chǔ)病中,高血壓是一個關(guān)鍵的危險因素。雖然目前還沒有發(fā)表相關(guān)研究報告,但我們認為高血壓可能是導(dǎo)致患者病情惡化和出現(xiàn)預(yù)后不良的重要因素?!?/p>
疫情在歐洲和美國的快速蔓延,使意大利等許多國家陷入危機。醫(yī)生正在努力應(yīng)對這種具有高傳染性的病原體。據(jù)世界衛(wèi)生組織,截至3月13日,在短短三個月內(nèi),全球已經(jīng)有超過13萬人感染了新型冠狀病毒,近5000人死亡。
面對這場全球蔓延的疫情,了解這種疾病的病程,識別面臨風險最高的人群,對于優(yōu)化治療方案至關(guān)重要。
我們可能需要研究中國龐大的患者群體才能找到答案。目前中國有15,000多名患者仍在住院治療,但新感染病例已經(jīng)大幅減少。有6%的患者病情惡化,并且惡化速度非??臁?/p>
杜斌說:“我們會密切關(guān)注老年人和高血壓患者。他們是我們工作的重點?!?/p>
除了高血壓以外,杜斌對新冠肺炎的治療還提出了以下觀點:
大膽使用呼吸機
杜斌說,當患者出現(xiàn)呼吸困難時,醫(yī)生應(yīng)該毫不猶豫地采取進一步措施,因為患者可能很快就出現(xiàn)器官衰竭。這意味著當微創(chuàng)輔助呼吸措施無法提高血氧飽和度時,醫(yī)生應(yīng)該積極干預(yù),采用有創(chuàng)通氣措施,在患者咽喉部位插管或者切開咽喉形成氣道。
他表示,需要有創(chuàng)機械通氣的患者接近一半最終死亡,但大多數(shù)康復(fù)患者都是很早就接受了有創(chuàng)通氣。
他說:“患者需要盡早使用有創(chuàng)通氣,沒有必要拖到太晚?!?/p>
專攻通氣和氧氣治療的呼吸科醫(yī)生,對于治療Covid-19重癥患者變得越來越重要,因為他們掌握更多相關(guān)知識,可以根據(jù)患者的情況調(diào)整呼吸機。
沒有“靈丹妙藥”
人們對開發(fā)治療這種病毒的藥物期望越來越高。正在測試治療方法的制藥公司獲得了投資者青睞,市值增加了數(shù)十億美元。但杜斌認為,僅靠藥物救不了患者,尤其是重癥患者。
他說,17年前的非典疫情導(dǎo)致近8000人感染。那次疫情的經(jīng)驗證明,多數(shù)患者沒有特定的抗病毒藥物就能治愈。他補充說,大量使用抗生素并沒有阻止細菌感染導(dǎo)致的死亡。
“當出現(xiàn)病毒感染的時候,我們都希望有一種藥物能殺死病毒,改變臨床結(jié)果。但實際上并沒有靈丹妙藥?!?/p>
相反,他認為,重癥監(jiān)護病房里??漆t(yī)生和護士團結(jié)合作,對于維持患者的生命更加重要。他說:“在重癥監(jiān)護病房里,醫(yī)生的工作應(yīng)該像管弦樂隊的指揮一樣,提供維持生命的治療,同時考慮不同專家的意見?!?/p>
再次感染的威脅
有報道稱,康復(fù)出院的患者再次檢測呈陽性甚至死亡,這引發(fā)了人們對于這種病毒可能以某種形式重新出現(xiàn)的擔憂。
但杜斌表示,患者在出院后幾天內(nèi)再次感染,“在理論上”沒有任何意義,因為患者血液中與病毒抗爭產(chǎn)生的抗體雖然不會一直存在,但也不會這么快消失。
他說:“對于復(fù)陽的患者,我們需要關(guān)注的是他們的陰性檢測結(jié)果的真實性?!崩纾鶕?jù)病毒所在的位置,對從同一位患者不同部位提取的樣本,可以進行不同的檢測。
他認為,不同廠家生產(chǎn)的檢測試劑盒也可能不一致,這也會影響檢測結(jié)果。(財富中文網(wǎng))
譯者:Biz
Patients with hypertension appear to be at a higher risk of dying from the coronavirus, said a top Chinese intensive care doctor who’s been treating critically ill patients since mid-January.
While there’s been no published research yet explaining why, Chinese doctors working in Wuhan, the central Chinese city where the virus first emerged, have noticed that infected patients with that underlying illness are more likely to slip into severe distress and die.
Of a group of 170 patients who died in January in Wuhan—the first wave of casualties caused by a pathogen that’s now raced around the world—nearly half had hypertension.
“That’s a very high ratio,” said Du Bin, director of the intensive care unit at Peking Union Medical College Hospital, in an interview with Bloomberg over the phone from Wuhan. He was among a team of top doctors sent to the devastated city two months ago to help treat patients there.
“From what I was told by other doctors and the data I can see myself, among all the underlying diseases, hypertension is a key dangerous factor,” said Du, one of the most respected critical care experts in China. “Though there is no research published on that yet, we believe hypertension could be an important factor in causing patients to deteriorate, leading to a bad prognosis.”
As the outbreak picks up speed in Europe and the U.S., plunging countries like Italy into crisis, doctors are struggling to treat the highly-infectious pathogen that’s infected over 108,000 people globally in just three months.
Understanding the course of the disease and identifying individuals at greatest risk are critical for optimizing care for a global contagion that’s killed more than 3,700 people since emerging in China in December.
Answers may lie in studying the large pool of patients in China, where more than 15,000 remain hospitalized although new infections have slowed dramatically. The disease turns critical in 6% of patients and deterioration can happen very quickly.
“We’ll keep an eye on old people and those with high blood pressure. They are the key focus,” said Du.
Besides the hypertension factor, Du’s other insights into treating the disease are:
Move aggressively to ventilate
Du said that doctors should not hesitate to escalate measures for patients facing respiratory distress, as organ failure can set in quickly after. That means doctors should intervene aggressively with invasive ventilation measures—inserting a tube into a patient’s throat or cutting the throat open to create an airway—when low blood oxygen levels can’t be improved by less invasive measures.
Almost half of the patients who require invasive mechanical ventilation end up dying, but most of those who recover are those who were put on invasive ventilation early, said Du.
“Patients need to use invasive ventilation as early as possible, there’s no point of doing it late,” he said.
Respiratory therapists—doctors that specialize in ventilation and oxygen treatment—are becoming all the more important in treating patients critically ill with Covid-19 as they are more knowledgeable and can fine-tune ventilators to suit patient conditions.
No "magic bullets" in drugs
There is growing anticipation over drugs being developed to treat the virus, with investors adding billions to the market value of pharmaceutical companies testing treatments now. But Du said drugs alone cannot save patients, especially those in severe condition.
The experience of SARS, the epidemic 17 years ago that sickened almost 8,000 people, showed that most patients can be cured without a specific anti-viral drug, said Du. And the abundance of antibiotics has not prevented deaths by bacterial infections, he added.
“When there’s a virus infection, we hope there’s a drug that can kill the virus and change the clinical outcome. But there’s no magic bullet.”
Instead, teamwork among specialists and nurses in intensive care units can be more crucial in keeping patients alive, he said. “An ICU doctor should work like a conductor in an orchestra to provide life-sustaining treatment while taking into consideration different specialist views,” he said.
Threat of re-infection
Reports that people who have recovered and been discharged from hospital later test positive again—and even die from the disease—have ignited fears that the virus can somehow re-emerge.
Du said that patients becoming re-infected again within days of leaving the hospital makes no sense “theoretically” as the anti-bodies in their bloodstream generated from fighting the disease do not disappear so quickly, although they don’t necessarily stay forever.
“What we need to look at in terms of those who tested positive again is concerns over the authenticity of their negative results,” he said. For example, samples taken from different areas of the same patient could test differently depending on where the virus resides.
Test kits made by different manufacturers could also have inconsistencies that impact test results, he said.